{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T12:40:46Z","timestamp":1769604046190,"version":"3.49.0"},"reference-count":40,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2017,1,1]],"date-time":"2017-01-01T00:00:00Z","timestamp":1483228800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100006306","name":"Sigrid Jus\u00e9lius Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006306","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Helsinki University Hospital Research Funds"},{"DOI":"10.13039\/501100009420","name":"Hospital District of Southwest Finland","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100009420","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Finnish Funding Agency for Technology and Innovation"},{"name":"Sladjana M. Crosley Foundation"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","gynecologiconcology-online.net","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2017,1]]},"DOI":"10.1016\/j.ygyno.2016.11.018","type":"journal-article","created":{"date-parts":[[2016,11,18]],"date-time":"2016-11-18T17:18:19Z","timestamp":1479489499000},"page":"83-89","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":22,"title":["Roles of human epididymis protein 4, carbohydrate antigen 125, inhibin B and anti-M\u00fcllerian hormone in the differential diagnosis and follow-up of ovarian granulosa cell tumors"],"prefix":"10.1016","volume":"144","author":[{"given":"Ulla-Maija","family":"Haltia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marianne","family":"Hallamaa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johanna","family":"Tapper","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johanna","family":"Hynninen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Henrik","family":"Alfthan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bhanu","family":"Kalra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7017-6931","authenticated-orcid":false,"given":"Olli","family":"Ritvos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Markku","family":"Heikinheimo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Leila","family":"Unkila-Kallio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Antti","family":"Perheentupa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3558-6617","authenticated-orcid":false,"given":"Anniina","family":"F\u00e4rkkil\u00e4","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ygyno.2016.11.018_bb0005","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1002\/cncr.21616","article-title":"Surgery by consultant gynecologic oncologists improves survival in patients with ovarian carcinoma","volume":"106","author":"Engelen","year":"2006","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.ygyno.2016.11.018_bb0010","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1093\/jnci\/djj019","article-title":"Effect of surgeon specialty on processes of care and outcomes for ovarian cancer patients","volume":"98","author":"Earle","year":"2006","journal-title":"J. Natl. Cancer Inst."},{"issue":"Suppl. 6","key":"10.1016\/j.ygyno.2016.11.018_bb0015","doi-asserted-by":"crossref","first-page":"vi24","DOI":"10.1093\/annonc\/mdt333","article-title":"Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"24","author":"Ledermann","year":"2013","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2016.11.018_bb0020","unstructured":"(NCCN) NCCN. Ovarian cancer including fallopian tube cancer and primary peritoneal cancer 2016 [Available from: http:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/ovarian.pdf."},{"issue":"8","key":"10.1016\/j.ygyno.2016.11.018_bb0025","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1038\/sj.bjc.6605011","article-title":"Serum HE4 concentration differentiates malignant ovarian tumours from ovarian endometriotic cysts","volume":"100","author":"Huhtinen","year":"2009","journal-title":"Br. J. Cancer"},{"issue":"4","key":"10.1016\/j.ygyno.2016.11.018_bb0030","doi-asserted-by":"crossref","DOI":"10.1016\/j.ajog.2011.05.017","article-title":"Human epididymis protein 4 offers superior specificity in the differentiation of benign and malignant adnexal masses in premenopausal women","volume":"205","author":"Holcomb","year":"2011","journal-title":"Am. J. Obstet. Gynecol."},{"issue":"13","key":"10.1016\/j.ygyno.2016.11.018_bb0035","first-page":"3695","article-title":"The HE4 (WFDC2) protein is a biomarker for ovarian carcinoma","volume":"63","author":"Hellstrom","year":"2003","journal-title":"Cancer Res."},{"issue":"3","key":"10.1016\/j.ygyno.2016.11.018_bb0040","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.ygyno.2011.02.022","article-title":"No benefit from combining HE4 and CA125 as ovarian tumor markers in a clinical setting","volume":"121","author":"Jacob","year":"2011","journal-title":"Gynecol. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2016.11.018_bb0045","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.ygyno.2016.01.016","article-title":"HE4, CA125 and risk of ovarian malignancy algorithm (ROMA) as diagnostic tools for ovarian cancer in patients with a pelvic mass: an Italian multicenter study","volume":"141","author":"Romagnolo","year":"2016","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2016.11.018_bb0050","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1007\/s13277-011-0256-4","article-title":"Human epididymis protein 4 reference limits and natural variation in a Nordic reference population","volume":"33","author":"Bolstad","year":"2012","journal-title":"Tumour Biol."},{"issue":"Pt 4","key":"10.1016\/j.ygyno.2016.11.018_bb0055","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1258\/acb.2011.011258","article-title":"Elevated human epididymis protein 4 concentrations in chronic kidney disease","volume":"49","author":"Nagy","year":"2012","journal-title":"Ann. Clin. Biochem."},{"issue":"10","key":"10.1016\/j.ygyno.2016.11.018_bb0060","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1111\/j.1471-0528.1990.tb02448.x","article-title":"A risk of malignancy index incorporating CA 125, ultrasound and menopausal status for the accurate preoperative diagnosis of ovarian cancer","volume":"97","author":"Jacobs","year":"1990","journal-title":"Br. J. Obstet. Gynaecol."},{"issue":"1","key":"10.1016\/j.ygyno.2016.11.018_bb0065","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.ygyno.2008.08.031","article-title":"A novel multiple marker bioassay utilizing HE4 and CA125 for the prediction of ovarian cancer in patients with a pelvic mass","volume":"112","author":"Moore","year":"2009","journal-title":"Gynecol. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2016.11.018_bb0070","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.ygyno.2012.07.106","article-title":"Evaluation of HE4, CA125, risk of ovarian malignancy algorithm (ROMA) and risk of malignancy index (RMI) as diagnostic tools of epithelial ovarian cancer in patients with a pelvic mass","volume":"127","author":"Karlsen","year":"2012","journal-title":"Gynecol. Oncol."},{"issue":"5","key":"10.1016\/j.ygyno.2016.11.018_bb0075","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1111\/ajo.12363","article-title":"HE4, CA125, the Risk of Malignancy Algorithm and the Risk of Malignancy Index and complex pelvic masses - a prospective comparison in the pre-operative evaluation of pelvic masses in an Australian population","volume":"55","author":"Richards","year":"2015","journal-title":"Aust. N Z J Obstet. Gynaecol."},{"issue":"1","key":"10.1016\/j.ygyno.2016.11.018_bb0080","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/bjc.2013.241","article-title":"Long-term follow-up is crucial after treatment for granulosa cell tumours of the ovary","volume":"109","author":"Mangili","year":"2013","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.ygyno.2016.11.018_bb0085","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1097\/IGC.0000000000000304","article-title":"Clinical characteristics and survival of patients with an adult-type ovarian granulosa cell tumor: a 56-year single-center experience","volume":"25","author":"Bryk","year":"2015","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"2","key":"10.1016\/j.ygyno.2016.11.018_bb0090","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ygyno.2015.05.011","article-title":"Stage I granulosa cell tumours: a management conundrum? Results of long-term follow up","volume":"138","author":"Wilson","year":"2015","journal-title":"Gynecol. Oncol."},{"issue":"26","key":"10.1016\/j.ygyno.2016.11.018_bb0095","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1056\/NEJMoa0902542","article-title":"Mutation of FOXL2 in granulosa-cell tumors of the ovary","volume":"360","author":"Shah","year":"2009","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.ygyno.2016.11.018_bb0100","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1210\/er.2011-0014","article-title":"Molecular pathogenesis of granulosa cell tumors of the ovary","volume":"33","author":"Jamieson","year":"2012","journal-title":"Endocr. Rev."},{"issue":"7","key":"10.1016\/j.ygyno.2016.11.018_bb0105","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1002\/ijc.29532","article-title":"The clinical utility of serum anti-Mullerian hormone in the follow-up of ovarian adult-type granulosa cell tumors - a comparative study with inhibin B","volume":"137","author":"Farkkila","year":"2015","journal-title":"Int. J. Cancer"},{"issue":"2","key":"10.1016\/j.ygyno.2016.11.018_bb0110","first-page":"540","article-title":"Detection of minimal levels of serum anti-Mullerian hormone during follow-up of patients with ovarian granulosa cell tumor by means of a highly sensitive enzyme-linked immunosorbent assay","volume":"85","author":"Long","year":"2000","journal-title":"J. Clin. Endocrinol. Metab."},{"issue":"1","key":"10.1016\/j.ygyno.2016.11.018_bb0115","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.ygyno.2013.06.030","article-title":"Pre-operative imaging with CA125 is a poor predictor for granulosa cell tumors","volume":"131","author":"Stine","year":"2013","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2016.11.018_bb0120","doi-asserted-by":"crossref","first-page":"158","DOI":"10.3802\/jgo.2009.20.3.158","article-title":"Prognostic factors in adult granulosa cell tumors of the ovary: a retrospective analysis of 80 cases","volume":"20","author":"Ayhan","year":"2009","journal-title":"J. Gynecol. Oncol."},{"issue":"5","key":"10.1016\/j.ygyno.2016.11.018_bb0125","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1111\/IGC.0b013e3181a702d1","article-title":"The role of inhibins B and antimullerian hormone for diagnosis and follow-up of granulosa cell tumors","volume":"19","author":"Geerts","year":"2009","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"9","key":"10.1016\/j.ygyno.2016.11.018_bb0130","doi-asserted-by":"crossref","first-page":"604","DOI":"10.7326\/0003-4819-150-9-200905050-00006","article-title":"A new equation to estimate glomerular filtration rate","volume":"150","author":"Levey","year":"2009","journal-title":"Ann. Intern. Med."},{"issue":"2 Suppl 1","key":"10.1016\/j.ygyno.2016.11.018_bb0135","first-page":"S1","article-title":"K\/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification, and stratification","volume":"39","author":"National","year":"2002","journal-title":"Am. J. Kidney Dis."},{"issue":"3","key":"10.1016\/j.ygyno.2016.11.018_bb0140","doi-asserted-by":"crossref","first-page":"837","DOI":"10.2307\/2531595","article-title":"Comparing the areas under two or more correlated receiver operating characteristic curves: a nonparametric approach","volume":"44","author":"DeLong","year":"1988","journal-title":"Biometrics"},{"issue":"9","key":"10.1016\/j.ygyno.2016.11.018_bb0145","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/j.jclinepi.2008.10.003","article-title":"Longitudinal tobit regression: a new approach to analyze outcome variables with floor or ceiling effects","volume":"62","author":"Twisk","year":"2009","journal-title":"J. Clin. Epidemiol."},{"issue":"7","key":"10.1016\/j.ygyno.2016.11.018_bb0150","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1097\/IGC.0000000000000477","article-title":"Should all cases of high-grade serous ovarian, tubal, and primary peritoneal carcinomas be reclassified as tubo-ovarian serous carcinoma?","volume":"25","author":"Moss","year":"2015","journal-title":"Int. J. Gynecol. Cancer"},{"issue":"3","key":"10.1016\/j.ygyno.2016.11.018_bb0155","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1097\/PAS.0000000000000353","article-title":"Incidental nonuterine high-grade serous carcinomas arise in the fallopian tube in most cases: further evidence for the tubal origin of high-grade serous carcinomas","volume":"39","author":"Gilks","year":"2015","journal-title":"Am. J. Surg. Pathol."},{"issue":"6","key":"10.1016\/j.ygyno.2016.11.018_bb0160","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1038\/modpathol.3800612","article-title":"Comprehensive analysis of HE4 expression in normal and malignant human tissues","volume":"19","author":"Galgano","year":"2006","journal-title":"Mod. Pathol."},{"issue":"2","key":"10.1016\/j.ygyno.2016.11.018_bb0165","first-page":"161","article-title":"Histologic subtypes of ovarian carcinoma: an overview","volume":"27","author":"Soslow","year":"2008","journal-title":"Int. J. Gynecol. Pathol."},{"issue":"2","key":"10.1016\/j.ygyno.2016.11.018_bb0170","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.ygyno.2010.06.031","article-title":"Adult granulosa cell tumors of the ovary: tumor dissemination pattern at primary and recurrent situation, surgical outcome","volume":"119","author":"Fotopoulou","year":"2010","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2016.11.018_bb0175","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1016\/j.ygyno.2016.10.002","article-title":"Characteristics and outcome of recurrence in molecularly defined adult-type ovarian granulosa cell tumors","volume":"143","author":"Bryk","year":"2016","journal-title":"Gynecol. Oncol."},{"issue":"11","key":"10.1016\/j.ygyno.2016.11.018_bb0180","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djw134","article-title":"Molecularly defined adult granulosa cell tumor of the ovary: the clinical phenotype","volume":"108","author":"McConechy","year":"2016","journal-title":"J. Natl Cancer Inst."},{"key":"10.1016\/j.ygyno.2016.11.018_bb0185","article-title":"FOXL2 402C>G mutation can be identified in the circulating tumor DNA of patients with adult-type granulosa cell tumor","author":"F\u00e4rkkil\u00e4 Anniina","year":"2016","journal-title":"J. Mol. Diagn."},{"issue":"3","key":"10.1016\/j.ygyno.2016.11.018_bb0190","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.ygyno.2012.03.011","article-title":"Serum HE4 concentration is not dependent on menstrual cycle or hormonal treatment among endometriosis patients and healthy premenopausal women","volume":"125","author":"Hallamaa","year":"2012","journal-title":"Gynecol. Oncol."},{"issue":"10","key":"10.1016\/j.ygyno.2016.11.018_bb0195","doi-asserted-by":"crossref","first-page":"3085","DOI":"10.1093\/humrep\/des260","article-title":"Anti-Mullerian hormone: poor assay reproducibility in a large cohort of subjects suggests sample instability","volume":"27","author":"Rustamov","year":"2012","journal-title":"Hum. Reprod."},{"issue":"5","key":"10.1016\/j.ygyno.2016.11.018_bb0200","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1093\/humrep\/deu036","article-title":"A single-centre evaluation of two new anti-Mullerian hormone assays and comparison with the current clinical standard assay","volume":"29","author":"Welsh","year":"2014","journal-title":"Hum. Reprod."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825816315748?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825816315748?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,6,25]],"date-time":"2022-06-25T15:55:54Z","timestamp":1656172554000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825816315748"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1]]},"references-count":40,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,1]]}},"alternative-id":["S0090825816315748"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2016.11.018","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2017,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Roles of human epididymis protein 4, carbohydrate antigen 125, inhibin B and anti-M\u00fcllerian hormone in the differential diagnosis and follow-up of ovarian granulosa cell tumors","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2016.11.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}